PDF(Pubmed)
Abstract：
Patients with metastatic gastric cancer had limited treatments and often had a somber prognosis, especially when patients were unable to tolerate high-intensity cytotoxic treatment due to poor physical condition or organ dysfunction after the failure of standard therapy. Here, we reported a metastatic and proficient mismatch repair (pMMR) gastric adenocarcinoma patient with the Eastern Cooperative Oncology Group (ECOG) performance status score of 2 associated with hypoproteinemia and fatigue, and poor appetite that was unable to tolerate high-intensity therapy after several chemotherapy regimens and anti-angiogenic therapy. After receiving novel triple-combination therapy, which consists of PD-1 inhibitor, Radiotherapy and Granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy (PRaG for short), the patient achieved a complete response (CR) with a progression-free survival time of 14 months, and ECOG performance status score improved from 2 to 0. A significant systemic effect was observed in this case and the PRaG triple-combination therapy might provide a novel treatment strategy for metastatic pMMR gastric cancer patients.
摘要：
转移性胃癌患者的治疗方法有限，预后通常很糟糕，特别是当患者在标准治疗失败后由于身体状况不佳或器官功能障碍而无法耐受高强度细胞毒性治疗时.这里,我们报道了一名转移性和熟练的错配修复（pMMR）胃腺癌患者，其东部肿瘤协作组（ECOG）的表现状态评分为2，与低蛋白血症和疲劳相关，和食欲不振，在几种化疗方案和抗血管生成治疗后无法耐受高强度治疗。在接受新型三联疗法后，由PD-1抑制剂组成，放疗和粒细胞-巨噬细胞集落刺激因子（GM-CSF）治疗（简称PRaG），患者达到完全缓解（CR），无进展生存时间为14个月，ECOG成绩状态评分从2分提高到0分。在这种情况下观察到显着的全身效应，PRaG三联疗法可能为转移性pMMR胃癌患者提供新的治疗策略。
